Back to top
more

Alcon (ALC)

(Delayed Data from NYSE)

$72.67 USD

72.67
772,155

-0.70 (-0.95%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $72.66 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (150 out of 247)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Glaukos Builds Dual Growth Engines Amid Market Headwinds

by Zacks Equity Research

GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.

Zacks Equity Research

Alcon's Q2 Earnings Beat Estimates, Revenues Miss, Stock Plunges

by Zacks Equity Research

ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.

Zacks Equity Research

Compared to Estimates, Alcon (ALC) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Stay Ahead of the Game With Alcon (ALC) Q2 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Alcon (ALC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Alcon Stock Gains Following UNITY VCS' Approval in Canada

by Zacks Equity Research

ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.

Zacks Equity Research

Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks

by Zacks Equity Research

GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.

Zacks Equity Research

Do Options Traders Know Something About Alcon Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to ALC stock based on the movements in the options market lately.

Zacks Equity Research

Is it Apt to Retain Alcon Stock in Your Portfolio for Now?

by Zacks Equity Research

ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.

Zacks Equity Research

COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?

by Zacks Equity Research

Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?

Zacks Equity Research

Alcon Stock Rises Following the FDA Approval of TRYPTYR

by Zacks Equity Research

FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.